Type 1 Interferon in the Human Intestine - A Co-ordinator of the Immune Response to the Microbiota

Inflammatory Bowel Diseases

Volumn 23, Issue 4, 2017, Pages 524-533

  Giles, Edward M ^a,b   Stagg, Andrew J ^a,c  

^a MONASH MEDICAL CENTRE   (Australia)

^b HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

colitis; Crohn's; inflammatory bowel disease; microbiota; type 1 interferon; Ulcerative colitis; virobiota

Indexed keywords

ANTIGEN; INTERFERON;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; AUTOINFLAMMATORY DISEASE; BACTERIAL CELL WALL; CELL FUNCTION; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); ENTERITIS; GASTROINTESTINAL TRACT; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; INTESTINE; INTESTINE MUCOSA; MICROFLORA; NONHUMAN; PLANT DEFENSE; PRIORITY JOURNAL; REVIEW; T CELL LYMPHOMA; ULCERATIVE COLITIS; VIRUS INFECTION; ANIMAL; IMMUNE SYSTEM; IMMUNOLOGY; INTESTINE FLORA; METABOLISM; MOUSE;

ANIMALS; GASTROINTESTINAL MICROBIOME; HUMANS; IMMUNE SYSTEM; INTERFERON TYPE I; INTESTINES; MICE;

EID: 85016197039     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000001078     Document Type: Review

References (129)

1. Kole A, He J, Rivollier A, et al. Type I IFNs regulate effector and regulatory T cell accumulation and anti-inflammatory cytokine production during T cell-mediated colitis. J Immunol. 2013;191:2771-2779.
2. Lee SE, Li X, Kim JC, et al. Type I interferons maintain foxp3 expression and T-regulatory cell functions under inflammatory conditions in mice. Gastroenterology. 2012;143:145-154.
3. Metidji A, Rieder SA, Glass DD, et al. IFN-a/b receptor signaling promotes regulatory T cell development and function under stress conditions. J Immunol. 2015;194:4265-4276.
4. Rauch I, Hainzl E, Rosebrock F, et al. Type I interferons have opposing effects during the emergence and recovery phases of colitis. Eur J Immunol. 2014;44:2749-2760.
5. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011;43:246-252.
6. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119-124.
7. Giles EM, Sanders TJ, McCarthy NE, et al. Regulation of human intestinal T-cell responses by type 1 interferon-STAT1 signaling is disrupted in inflammatory bowel disease. Mucosal Immunol. 2016; 10:184-193.
8. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci. 1957;147:258-267.
9. Gough DJ, Messina NL, Clarke CJ, et al. Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity. 2012; 36:166-174.
10. Schulz O, Diebold SS, Chen M, et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature. 2005;433:887-892.
11. Fitzgerald KA, Rowe DC, Barnes BJ, et al. LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF. J Exp Med. 2003;198:1043-1055.
12. Cavlar T, Ablasser A, HornungV. Induction of type I IFNs by intracellular DNA-sensing pathways. Immunol Cell Biol. 2012;90:474-482.
13. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004;303: 1526-1529.
14. Crouse J, Kalinke U, Oxenius A. Regulation of antiviral T cell responses by type I interferons. Nat Rev Immunol. 2015;15:231-242.
15. Honda K, Yanai H, Negishi H, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature. 2005;434:772-777.
16. Kawai T, Takahashi K, Sato S, et al. IPS-1, an adaptor triggering RIG-I-and Mda5-mediated type I interferon induction. Nat Immunol. 2005;6: 981-988.
17. Meylan E, Curran J, Hofmann K, et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature. 2005; 437:1167-1172.
18. Watanabe T, Asano N, Kitani A, et al. Activation of type IIFN signaling by NOD1 mediates mucosal host defense against Helicobacter pylori infection. Gut Microbes. 2011;2:61-65.
19. Pandey AK, Yang Y, Jiang Z, et al. NOD2, RIP2 and IRF5 play a critical role in the type I interferon response to Mycobacterium tuberculosis. PLoSPathog. 2009;5:e1000500.
20. Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol. 2009;21:317-337.
21. Abt MC, Osborne LC, Monticelli LA, et al. Commensal bacteria calibrate the activation threshold of innate antiviral immunity. Immunity. 2012;37:158-170.
22. Yamamoto M, Yamaguchi R, Munakata K, et al. A microarray analysis of gnotobiotic mice indicating that microbial exposure during the neonatal period plays an essential role in immune system development. BMC Genomics. 2012;13:335.
23. Ganal SC, Sanos SL, Kallfass C, et al. Priming of natural killer cells by nonmucosal mononuclear phagocytes requires instructive signals from commensal microbiota. Immunity. 2012;37:171-186.
24. Tovey MG, Streuli M, Gresser I, et al. Interferon messenger RNA is produced constitutively in the organs of normal individuals. Proc Natl Acad Sci USA. 1987;84:5038-5042.
25. Asselin-Paturel C, Boonstra A, Dalod M, et al. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat Immunol. 2001;2:1144-1150.
26. Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science. 1999;284: 1835-1837.
27. Vogel SN, Fertsch D. Endogenous interferon production by endotoxin-responsive macrophages provides an autostimulatory differentiation signal. Infect Immun. 1984;45:417-423.
28. Jung A, Kato H, Kumagai Y, et al. Lymphocytoid choriomeningitis virus activates plasmacytoid dendritic cells and induces a cytotoxic T-cell response via MyD88. J Virol. 2008;82:196-206.
29. Kumagai Y, Takeuchi O, Kato H, et al. Alveolar macrophages are the primary interferon-alpha producer in pulmonary infection with RNA viruses. Immunity. 2007;27:240-252.
30. Barbalat R, Lau L, Locksley RM, et al. Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands. Nat Immunol. 2009;10:1200-1207.
31. Johansson C, Wetzel JD, He J, et al. Type I interferons produced by hematopoietic cells protect mice against lethal infection by mammalian reovirus. J Exp Med. 2007;204:1349-1358.
32. Shornick LP, Wells AG, Zhang Y, et al. Airway epithelial versus immune cell Stat1 function for innate defense against respiratory viral infection. J Immunol. 2008;180:3319-3328.
33. Watanabe T, Asano N, Fichtner-Feigl S, et al. NOD1 contributes to mouse host defense against Helicobacter pylori via induction of type I IFN and activation of the ISGF3 signaling pathway. J Clin Invest. 2010; 120:1645-1662.
34. Nakahashi-Oda C, Udayanga KG, Nakamura Y, et al. Apoptotic epithelial cells control the abundance of Treg cells at barrier surfaces. Nat Immunol. 2016;17:441-450.
35. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014;14:36-49.
36. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5:375-386.
37. Cho SS, Bacon CM, Sudarshan C, et al. Activation of STAT4 by IL-12 and IFN-alpha: evidence for the involvement of ligand-induced tyrosine and serine phosphorylation. J Immunol. 1996;157:4781-4789.
38. Fasler-Kan E, Pansky A, Wiederkehr M, et al. Interferon-alpha activates signal transducers and activators of transcription 5 and 6 in Daudi cells. Eur J Biochem. 1998;254:514-519.
39. Matikainen S, Sareneva T, Ronni T, et al. Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. Blood. 1999;93: 1980-1991.
40. Rusinova I, Forster S, Yu S, et al. Interferome v2.0: an updated database of annotated interferon-regulated genes. Nucleic Acids Res. 2013;41: D1040-D1046.
41. Thomas C, Moraga I, Levin D, et al. Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell. 2011; 146:621-632.
42. Mostafavi S, Yoshida H, Moodley D, et al. Parsing the interferon tran-scriptional network and its disease associations. Cell. 2016;164: 564-578.
43. Wang P, Zhu S, Yang L, et al. Nlrp6 regulates intestinal antiviral innate immunity. Science. 2015;350:826-830.
44. Stockinger S, Duerr CU, Fulde M, et al. TRIF signaling drives homeo-static intestinal epithelial antimicrobial peptide expression. J Immunol. 2014;193:4223-4234.
45. Swamy M, Abeler-Dörner L, Chettle J, et al. Intestinal intraepithelial lymphocyte activation promotes innate antiviral resistance. Nat Com-mun. 2015;6:7090.
46. Saxena K, Simon LM, Zeng X-L, et al. A paradox of transcriptional and functional innate interferon responses of human intestinal enteroids to enteric virus infection. Proc Natl Acad Sci U S A. 2017;114:E570-E579.
47. McFarland AP, Savan R, Wagage S, et al. Localized delivery of inter-feron-b by Lactobacillus exacerbates experimental colitis. PLoS One. 2011;6:e16967.
48. Rachmilewitz D, Katakura K, Karmeli F, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology. 2004;126:520-528.
49. Abe K, Nguyen KP, Fine SD, et al. Conventional dendritic cells regulate the outcome of colonic inflammation independently of T cells. Proc Natl Acad Sci U S A. 2007;104:17022-17027.
50. Katakura K, Lee J, Rachmilewitz D, et al. Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J Clin Invest. 2005; 115:695-702.
51. Hofmann C, Dunger N, Grunwald N, et al. T cell-dependent protective effects of CpG motifs of bacterial DNA in experimental colitis are mediated by CD11c+ dendritic cells. Gut. 2010;59:1347-1354.
52. Sainathan SK, Bishnupuri KS, Aden K, et al. Toll-like receptor-7 ligand Imiquimod induces type I interferon and antimicrobial peptides to ameliorate dextran sodium sulfate-induced acute colitis. Inflamm Bowel Dis. 2012;18:955-967.
53. Mirpuri J, Brazil JC, Berardinelli AJ, et al. Commensal Escherichia coli reduces epithelial apoptosis through IFN-alphaA-mediated induction of guanylate binding protein-1 in human and murine models of developing intestine. J Immunol. 2010;184:7186-7195.
54. Guarda G, Braun M, Staehli F, et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity. 2011;34:213-223.
55. Auerbuch V, Brockstedt DG, Meyer-Morse N, et al. Mice lacking the type I interferon receptor are resistant to Listeria monocytogenes. J Exp Med. 2004;200:527-533.
56. O'Connell RM, Saha SK, Vaidya SA, et al. Type I interferon production enhances susceptibility to Listeria monocytogenes infection. J Exp Med. 2004;200:437-445.
57. Stanley SA, Johndrow JE, Manzanillo P, et al. The Type I IFN response to infection with Mycobacterium tuberculosis requires ESX-1-mediated secretion and contributes to pathogenesis. J Immunol. 2007;178:3143-3152.
58. Antonelli LR, Gigliotti Rothfuchs A, Gonçalves R, et al. Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population. J Clin Invest. 2010;120:1674-1682.
59. Karaghiosoff M, Steinborn R, Kovarik P, et al. Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nat Immunol. 2003;4:471-477.
60. Henry T, Brotcke A, Weiss DS, et al. Type I interferon signaling is required for activation of the inflammasome during Francisella infection. J Exp Med. 2007;204:987-994.
61. Mancuso G, Midiri A, Biondo C, et al. Type I IFN signaling is crucial for host resistance against different species of pathogenic bacteria. J Immunol. 2007;178:3126-3133.
62. Parker D, Martin FJ, Soong G, et al. Streptococcus pneumoniae DNA initiates type I interferon signaling in the respiratory tract. MBio. 2011;2: e00016-00011.
63. Le Bon A, Durand V, Kamphuis E, et al. Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming. J Immunol. 2006;176:4682-4689.
64. Proietti E, Bracci L, Puzelli S, et al. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol. 2002;169:375-383.
65. Teijaro JR, Ng C, Lee AM, et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science. 2013;340:207-211.
66. Wilson EB, Yamada DH, Elsaesser H, et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science. 2013; 340:202-207.
67. Odorizzi PM, Wherry EJ. Immunology. An interferon paradox. Science. 2013;340:155-156.
68. Shulzhenko N, Morgun A, Hsiao W, et al. Crosstalk between B lymphocytes, microbiota and the intestinal epithelium governs immunity versus metabolism in the gut. Nat Med. 2011;17:1585-1593.
69. Markowitz CE. Interferon-beta: mechanism of action and dosing issues. Neurology. 2007;68:S8-S11.
70. Vandenbark AA, Huan J, Agotsch M, et al. Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis. J Neuroimmunol. 2009; 215:125-128.
71. Axtell RC, de Jong BA, Boniface K, et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med. 2010;16:406-412.
72. Wang X, Chen M, Wandinger KP, et al. IFN-beta-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: relevance to IFN-beta-1b therapeutic effects in multiple sclerosis. J Immunol. 2000;165:548-557.
73. Rogge L, D'Ambrosio D, Biffi M, et al. The role of Stat4 in species-specific regulation of Th cell development by type I IFNs. J Immunol. 1998;161:6567-6574.
74. Shibuya H, Nagai T, Ishii A, et al. Differential regulation of Th1 responses and CD154 expression in human CD4+ T cells by IFN-alpha. Clin Exp Immunol. 2003;132:216-224.
75. Nguyen KB, Cousens LP, Doughty LA, et al. Interferon alpha/beta-mediated inhibition and promotion of interferon gamma: STAT1 resolves a paradox. Nat Immunol. 2000;1:70-76.
76. Ramos HJ, Davis AM, George TC, et al. IFN-alpha is not sufficient to drive Th1 development due to lack of stable T-bet expression. J Immunol. 2007;179:3792-3803.
77. Yoo JK, Baker DP, Fish EN. Interferon-b modulates type 1 immunity during influenza virus infection. Antivir Res. 2010;88:64-71.
78. Nguyen KB, Watford WT, Salomon R, et al. Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science. 2002;297:2063-2066.
79. Jiang DK, Wu X, Qian J, et al. Genetic variation in STAT4 predicts response to interferon-a therapy for hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2016;63:1102-1111.
80. Carrero JA, Calderon B, Unanue ER. Type I interferon sensitizes lymphocytes to apoptosis and reduces resistance to Listeria infection. J Exp Med. 2004;200:535-540.
81. Kaser A, Nagata S, Tilg H. Interferon alpha augments activation-induced T cell death by upregulation of Fas (CD95/APO-1) and Fas ligand expression. Cytokine. 1999;11:736-743.
82. Dondi E, Roué G, Yuste VJ, et al. A dual role of IFN-alpha in the balance between proliferation and death of human CD4+ T lymphocytes during primary response. J Immunol. 2004;173:3740-3747.
83. Pilling D, Akbar AN, Girdlestone J, et al. Interferon-beta mediates stromal cell rescue of T cells from apoptosis. Eur J Immunol. 1999;29: 1041-1050.
84. Merigan TC, Oldstone MB, Welsh RM. Interferon production during lymphocytic choriomeningitis virus infection of nude and normal mice. Nature. 1977;268:67-68.
85. Crouse J, Bedenikovic G, Wiesel M, et al. Type I interferons protect T cells against NK cell attack mediated by the activating receptor NCR1. Immunity. 2014;40:961-973.
86. Xu HC, Grusdat M, Pandyra AA, et al. Type I interferon protects antiviral CD8+ T cells from NK cell cytotoxicity. Immunity. 2014;40: 949-960.
87. Havenar-Daughton C, Kolumam GA, Murali-Krishna K. Cutting Edge: the direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection. J Immunol. 2006;176:3315-3319.
88. Srivastava S, Koch MA, Pepper M, et al. Type I interferons directly inhibit regulatory T cells to allow optimal antiviral T cell responses during acute LCMV infection. J Exp Med. 2014;211:961-974.
89. Tough DF. Modulation of T-cell function by type I interferon. Immunol Cell Biol. 2012;90:492-497.
90. Bromberg JF, Horvath CM, Wen Z, et al. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci USA. 1996;93:7673-7678.
91. Tanabe Y, Nishibori T, Su L, et al. Cutting edge: role of STAT1, STAT3, and STAT5 in IFN-alpha beta responses in T lymphocytes. J Immunol. 2005;174:609-613.
92. Gil MP, Salomon R, Louten J, et al. Modulation of STAT1 protein levels: a mechanism shaping CD8 T-cell responses in vivo. Blood. 2006;107:987-993.
93. Stark GR, Kerr IM, Williams BR, et al. How cells respond to interferons. Annu Rev Biochem. 1998;67:227-264.
94. Regis G, Pensa S, Boselli D, et al. Ups and downs: the STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling. Semin Cell Dev Biol 2008;19:351-359.
95. Bleich A, Janus LM, Smoczek A, et al. CpG motifs of bacterial DNA exert protective effects in mouse models of IBD by antigen-independent tolerance induction. Gastroenterology. 2009;136:278-287.
96. Hall JA, Bouladoux N, Sun CM, et al. Commensal DNA limits regulatory T cell conversion and is a natural adjuvant of intestinal immune responses. Immunity. 2008;29:637-649.
97. Bilsborough J, George TC, Norment A, et al. Mucosal CD8alpha+ DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties. Immunology. 2003; 108:481-492.
98. Radulovic K, Manta C, Rossini V, et al. CD69 regulates type I IFN-induced tolerogenic signals to mucosal CD4 T cells that attenuate their colitogenic potential. J Immunol. 2012;188:2001-2013.
99. Neurath MF. New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol. 2014;7:6-19.
100. Madsen SM, Schlichting P, Davidsen B, et al. An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis. Am J Gastro-enterol. 2001;96:1807-1815.
101. Musch E, Andus T, Malek M, et al. Successful treatment of steroid refractory active ulcerative colitis with natural interferon-beta-an open long-term trial. Z Gastroenterol. 2007;45:1235-1240.
102. Nikolaus S, Rutgeerts P, Fedorak R, et al. Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut. 2003;52:1286-1290.
103. Seow CH, Benchimol EI, Griffiths AM, et al. Type I interferons for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2008;CD006790.
104. Moschen AR, Geiger S, Krehan I, et al. Interferon-alpha controls IL-17 expression in vitro and in vivo. Immunobiology. 2008;213:779-787.
105. Mannon PJ, Hornung RL, Yang Z, et al. Suppression of inflammation in ulcerative colitis by interferon-b-1a is accompanied by inhibition of IL-13 production. Gut. 2011;60:449-455.
106. Musch E, Lutfi T, von Stein P, et al. Topical treatment with the Toll-like receptor agonist DIMS0150 has potential for lasting relief of symptoms in patients with chronic active ulcerative colitis by restoring glucocorti-coid sensitivity. Inflamm Bowel Dis. 2013;19:283-292.
107. Mitoro A, Yoshikawa M, Yamamoto K, et al. Exacerbation of ulcerative colitis during alpha-interferon therapy for chronic hepatitis C. Intern Med. 1993;32:327-331.
108. Samson M, Audia S, Duchêne C, et al. Crohn's disease during the course of multiple sclerosis: role of interferon-beta therapy [in French]. Rev Med Interne. 2009;30:816-819.
109. Watanabe T, Hirono H, Hasegawa K, et al. Literature review in cases with exacerbation of ulcerative colitis induced by treatment with interferon and/or ribavirin. J Gastroenterol Hepatol. 2011;26: 1709-1716.
110. González-Navajas JM, Lee J, David M, et al. Immunomodulatory functions of type I interferons. Nat Rev Immunol. 2012;12:125-135.
111. Crow YJ, Manel N. Aicardi-Goutières syndrome and the type I interfer-onopathies. Nat Rev Immunol. 2015;15:429-440.
112. Di Sabatino A, Pickard KM, Gordon JN, et al. Evidence for the role of interferon-alfa production by dendritic cells in the Th1 response in celiac disease. Gastroenterology. 2007;133:1175-1187.
113. Baumgart DC, Metzke D, Guckelberger O, et al. Aberrant plasmacytoid dendritic cell distribution and function in patients with Crohn's disease and ulcerative colitis. Clin Exp Immunol. 2011;166:46-54.
114. Reinisch W, de Villiers W, Bene L, et al. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis. 2010;16:233-242.
115. Buruiana FE, Solà I, Alonso-Coello P. Recombinant human interleukin 10 for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2010;CD005109.
116. Weiss G, Rasmussen S, Zeuthen LH, et al. Lactobacillus acidophilus induces virus immune defence genes in murine dendritic cells by a Toll-like receptor-2-dependent mechanism. Immunology. 2010;131:268-281.
117. Weiss G, Rasmussen S, Nielsen Fink L, et al. Bifidobacterium bifidum actively changes the gene expression profile induced by Lactobacillus acidophilus in murine dendritic cells. PLoS One. 2010;5:e11065.
118. Kawashima T, Kosaka A, Yan H, et al. Double-Stranded RNA of intestinal commensal but not pathogenic bacteria triggers production of protective interferon-b. Immunity. 2013;38:1187-1197.
119. Tschurtschenthaler M, Wang J, Fricke C, et al. Type I interferon signalling in the intestinal epithelium affects Paneth cells, microbial ecology and epithelial regeneration. Gut. 2014;63:1921-1931.
120. Deriu E, Boxx GM, He X, et al. Influenza virus affects intestinal micro-biota and secondary Salmonella infection in the gut through type I in-terferons. PLoS Pathog. 2016;12:e1005572.
121. Mumphrey SM, Changotra H, Moore TN, et al. Murine norovirus 1 infection is associated with histopathological changes in immunocompe-tent hosts, but clinical disease is prevented by STAT1-dependent inter-feron responses. J Virol. 2007;81:3251-3263.
122. Kernbauer E, Ding Y, Cadwell K. An enteric virus can replace the beneficial function of commensal bacteria. Nature. 2014;516:94-98.
123. Yang JY, Kim MS, Kim E, et al. Enteric viruses ameliorate gut inflammation via toll-like receptor 3 and toll-like receptor 7-mediated inter-feron-b production. Immunity. 2016;44:889-900.
124. Duerkop BA, Hooper LV. Resident viruses and their interactions with the immune system. Nat Immunol. 2013;14:654-659.
125. Virgin HW, Wherry EJ, Ahmed R. Redefining chronic viral infection. Cell. 2009;138:30-50.
126. Norman JM, Handley SA, Baldridge MT, et al. Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell. 2015; 160:447-460.
127. Cadwell K, Patel KK, Maloney NS, et al. Virus-plus-susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine. Cell. 2010;141:1135-1145.
128. Basic M, Keubler LM, Buettner M, et al. Norovirus triggered microbiota-driven mucosal inflammation in interleukin 10-deficient mice. Inflamm Bowel Dis. 2014;20:431-443.
129. Pane JA, Webster NL, Coulson BS. Rotavirus activates lymphocytes from non-obese diabetic mice by triggering toll-like receptor 7 signaling and interferon production in plasmacytoid dendritic cells. PLoS Pathog. 2014;10:e1003998.